Overview

A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
0
Participant gender:
All
Summary
Primary Objective: To determine objective response rate (ORR). Secondary Objectives: To assess duration of response (DR), progression free survival (PFS) and overall survival (OS). To evaluate global safety profile. To determine pharmacokinetic profile. To assess clinical utility of fluorescence in situ hybridization (FISH) assay in selection of patients with mesenchymal-epithelial hybridization (MET) gene amplification. To assess lung cancer symptoms, health-related quality of life and treatment satisfaction.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Sanofi
Criteria
Inclusion criteria:

Metastatic non-small-cell lung cancer patients with progressive disease during or after
first or second line therapy harboring MET gene amplification and with measurable disease
by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.

Exclusion criteria:

Patient less than 18 years old. Eastern Cooperative Oncology Group (ECOG) performance
status >2. More than 2 episodes of disease progression under anticancer therapy. Wash out
period of less than 3 weeks from prior treatment with chemotherapy, radiotherapy or,
surgery or any investigational treatment.

Adequate hematologic, hepatic, renal, coagulation, and metabolic functions. No resolution
of any specific toxicities (excluding alopecia) related to any prior anti-cancer therapy to
grade ≤1 according to the National Cancer Institute-Common Terminology Criteria for Adverse
Events (NCI CTCAE) v.4.03.

Pregnant or breast-feeding women. Patient with reproductive potential without method of
contraception. Symptomatic brain metastasis. Any clinically significant medical condition
other than cancer which could interfere with the safe delivery of study treatment or risk
of toxicity.

Known hypersensitivity or any adverse event related to the study drug excipient
(Captisol®).

Prior treatment with any MET Tyrosine Kinase Inhibitors (TKIs) or anti-MET antibodies
(excluding onartuzumab).

Patients treated with potent CYP3A inhibitor unless it can be discontinued. Patients
treated with potent and moderate CYP3A inducers unless it can be discontinued.

Mean QTc interval prolongation >470 msec.

The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.